Assessing the Risk of Epstein-Barr Virus–Related Lymphoproliferative Disorders Before Administration of Visilizumab - ScienceDirect

Gastroenterology

Volume 134, Issue 3, March 2008, Pages 895-896

Gastroenterology

https://doi.org/10.1053/j.gastro.2008.01.023 Get rights and content

References (3)

S. Plevy et al.
A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis
Gastroenterology
(2007)

There are more references available in the full text version of this article.

Cited by (0)

Copyright © 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.